CRISPR/Cas9, a new approach to successful knockdown of ABCB1/P-glycoprotein and reversal of chemosensitivity in human epithelial ovarian cancer cell line
Open Access
- 1 February 2018
- journal article
- research article
- Vol. 21 (2) , 181-187
Abstract
Objective(s): Multidrug resistance (MDR) is a major obstacle in the successful chemotherapy of ovarian cancer. Inhibition of P-glycoprotein (P-gp), a member of ATP-binding cassette (ABC) transporters, is a well-known strategy to overcome MDR in cancer. The aim of this study was to investigate the efficiency and ability of CRISPR/Cas9 genome editing technology to knockdown ABCB1 gene expression in adriamycin resistant (A2780/ADR) ovarian cancer cell line and evaluate the sensitivity changes to doxorubicin. Materials and Methods: Three single-guide RNAs (sgRNAs) targeting the fourth and fifth exons of human ABCB1 gene were designed in this study. Expression level of ABCB1 was detected using quantitative real time PCR (qRT-PCR) after co-transfection of all three sgRNAs into A2780/ADR cell line and subsequent antibiotic selection. Drug sensitivity to doxorubicin was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Results: The results showed that CRISPR/Cas9 system could significantly reduce the expression of P-gp. The dramatic decline in ABCB1 gene expression was associated with increased sensitivity of cells transfected with sgRNAs to doxorubicin. Conclusion: Based on the results of this study, it is concluded that the CRISPR-based systems, used in the present study, effectively down-regulated the target gene and acted as an ideal and cost-effective tool for gene editing of A2780/ADR cell line resulting in restoration of nonmalignant phenotype.Keywords
This publication has 36 references indexed in Scilit:
- Targeting ABCB1-mediated tumor multidrug resistance by CRISPR/Cas9-based genome editing.2016
- CRISPR/cas9, a novel genomic tool to knock down microRNA in vitro and in vivoScientific Reports, 2016
- In silico identified targeted inhibitors of P‐glycoprotein overcome multidrug resistance in human cancer cells in culturePharmacology Research & Perspectives, 2015
- High-throughput functional genomics using CRISPR–Cas9Nature Reviews Genetics, 2015
- Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological SubtypesPLOS ONE, 2014
- Current standards of care for chemotherapy of optimally cytoreduced advanced epithelial ovarian cancerGynecologic Oncology, 2013
- ZFN, TALEN, and CRISPR/Cas-based methods for genome engineeringTrends in Biotechnology, 2013
- Multiple Drug Resistance Mechanisms in CancerMolecular Biotechnology, 2010
- The molecular basis of multidrug resistance in cancer: The early years of P‐glycoprotein researchFEBS Letters, 2005
- MDR1 Gene Expression and Outcome in Osteosarcoma: A Prospective, Multicenter StudyJournal of Clinical Oncology, 2000